A deeper understanding of TME heterogeneity, T-cell exhaustion, and irAE mechanisms will be essential to refine the therapeutic positioning of CTLA-4 blockade within the evolving landscape of lung cancer immunotherapy. The gene discussed is CTLA4; the disease is lung cancer.